natgillin/translations-raw huggingface dataset:
The composition according to claim 1, wherein component (A) is 3difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-dichloromethylidene-benzonorbornene-5-yl) amide and component (B2) is selected from the group consisting of difenoconazole, propiconazole, cyproconazole and epoxiconazole. 
Pripravak prema zahtjevu 1, naznačen time da kao komponentu (A) sadrži spoj 3-difluorometil-1-metil-1 Hpirazol-4-karboksilna kiselina (9-diklorometiliden-benzonorbornen-5-iljamid, te kao komponentu (B) spoj koji je izabran između slijedećeg: difenokonazola, propikonazola, kiprokonazola i epoksikonazola.
The method of claim 9, wherein step (i) further comprises extending the 3' end of the first digested nucleic acid and/or the second nucleic acid. 
Postupak iz patentnog zahtjeva 7 ili 8, naznačen time, što korak (c) uključuje još i produžavanje 3’ kraja prve digestirane nukleinske kiseline i/ili druge digestirane nukleinske kiseline.
Such drugs were proposed as a means for overcoming the problems arising with the use of antipsychotics of the previous generation, namely, the typical antipsychotics, associated with major and severe side effects. 
Takvi lijekovi predloženi su kao sredstva za prevladavanje problema koji nastaju s uporabom antipsihotika prethodne generacije, to jest, tipičnih antipsihotika, povezanih sa velikim i ozbiljnim nuspojavama.
a demodulator configured to demodulate the received signal by use of an Orthogonal Frequency Division Multiplexing(OFDM) method; 
sredstvo (r104) za demoduliranje primljenog emitiranog signala ortogonalnom modulacijskom metodom u frekvencijskoj domeni, OFDM;
The compound of claim 1, wherein 
Spoj prema zahtjevu 1, gdje
Fig. 19.1 to 19.2, show perspective views of a device to carry out the novel process for the manufacture of a veneer. 
Slike 19.1 do 19.2 prikazuju pogled u perspektivi na uređaj za izvođenje novog postupka za proizvodnju furnira.
The pharmaceutical composition of any one of claims 1 to 13 characterized in that the viscosity is at least 2,000 cps and not more than 35,000 cps. 
Farmaceutski pripravak iz bilo kojeg od patentnih zahtjeva 1 do 10, naznačen time, da viskozitet iznosi najmanje 2,000 cps i ne više od 35,000 cps.
dividing the thus obtained oatmeal into a first coarse fraction and a first fine fraction, said first coarse fraction comprising a B-glucan concentrate having a B-glucan content of 30 to 40%, and said first fine fraction comprising a starch concentrate having a starch content of more than 65%, preferably more than 70%, and said division being performed by using one or more operations selected from sieving and air classification and, optionally, dry milling, 
(c) dijeljenje tako dobivenog zobenog brašna u prvu grubu frakciju i prvu finu frakciju, ta prva gruba frakcija sadrži koncentrat fB-glukana sa sadržajem B-glukana od 30 do 40%, 1 ta prva fina frakcija sadrži koncentrat škroba sa sadržajem škroba većim od 65%, poželjno većim od 70%, i ovo dijeljenje se provodi uporabom jedne ili više operacija izabranih između prosijavanja 1 klasifikacije zrakom, 1 po izboru, suhog mljevenja,
The composition of any of claims 1 to 5, comprising PTH at a concentration of 1.4 mg/ml, methionine at a concentration of 2 mg/ml, a poloxamer at a concentration of 0.3 mg/ml, and a physiologically acceptable buffering agent that maintains the pH of the formulation at a pH of 5.5. 
Sastav prema bilo kojem zahtjevu 1 do 5, naznačen time, da sadrži PTH u koncentraciji od 1,4 mg/ml, metionin u koncentraciji od 2 mg/ml, poloksamer u koncentraciji od 0,3 mg/ml, i fiziološki prihvatljivo pufersko sredstvo koje održava pH formulacije na pH 5,5.
1 mixing member; FIG. 3 shows a partly exploded front view of the FIG. 
Slika 3 prikazuje djelomično izmaknuti pogled sprijeda dijela Slike 2 članka za miješanje;
A peptide consisting of the amino acid sequence according to SEQ ID No. 6 for use in the treatment of cancer. 
HR P20190202 T1 HR P20190202 T1 PATENTNI ZAHTJEVI 1. = Peptid koji se sastoji od sekvence aminokiselina prema SEQ ID br. 10.
glycine, proline, a natural or synthetic film-forming polymer, 
glicin, prolin, prirodni ili sintetički polimer koji tvori film,
As used here, schizophrenic disorders include paranoid, disorganized, catatonic, undifferentiated and residual schizophrenia, schizophreniform disorder, shcizoaffective disorder, delusional disorder, brief psychotic disorder and psychotic disorder not specified. 
Kao što se ovdje upotrebljava, poremećaji shizofrenije uključuje paranoidnu, katatoničnu, nediferenciranu i rezidualnu shizofreniju, shizofreniformni poremećaj, shizoafektivni poremećaj, poremećaj obmane, kratki psihotički poremećaj i nespecifični psihotički poremećaj.
freezing the mixture in the mold, and 
(d) smrzavanje mješavine u kalupu, i
A method according to one or more of claims 1 to 5, wherein the packet continuity counter function is disabled in said modulators (5,6). 
Metoda prema jednom ili više od patentnih zahtjeva 1 do 5, gdje funkcija brojača kontinuiteta paketa je onemogućena u navedenim modulatorima (5,6).
An isolated antibody or protein comprising a heavy chain sequence of SEQ ID NO:75 and a light chain sequence of SEQ ID NO:71. 
Vektor kloniranja ili ekspresije prema zahtjevu 27, naznačen time, da obuhvaća barem jednu nukleinsku kiselinu odabranu iz skupine koju čine od SEQ ID NO:79 do SEQ ID NO:86.
wherein R1 is difluoromethyl or trifluoromethyl and X is chloro, fluoro or bromo; and (B) at least one compound selected from compounds known for their fungicidal activity; and a method of controlling diseases on useful plants, especially rust diseases on soybean plants. 
Pripravak pogodan za kontrolu bolesti uzrokovanih fitopatogenima koji se sastoji od: (A) spoja formule (I) naznačen time da R1 je difluorometil ili trifluorometil i X je kloro, fluoro ili bromo; i (B) spoj fenpropidin.
The method according to claim 1, wherein said obesity or diabetes is dietary fat-related. 
Metoda u skladu s patentnim zahtjevom 1, pri čemu su pretilost ili dijabetes povezani s masnoćama u prehrani.
International Publication No's. 
Broj međunarodne objave:
The system according to claim 1, which further comprises a cut-off switch that turns off the pump motor and opens the recirculation valve. 
Sustav prema zahtjevu 1, naznačen time da nadalje sadrži prekidač (30) koji isključuje motor pumpe i otvara recirkulacijski ventil.
A compound as claimed in any of claims 1 to 5 or a composition as claimed in claim 6 for use in the treatment of familial amyloid polyneuropathy, familial amyloid cardiomyopathy, leptomeningeal amyloidosis, senile systemic amyloidosis, central amyloidosis ocular amyloidosis, vitreous amyloidosis, or CNS amyloidsis. 
Spoj prema bilo kojem od zahtjeva 1 do 5, ili sastav prema zahtjevu 6, naznačen time, da se upotrebljava u liječenju porodične amiloidne polineuropatije, porodične amiloidne kardiomiopatije, leptomeningne amiloidoze, senilne sustavne amiloidoze, centralne amiloidoze, okularne amiloidoze, amiloidoze staklovine, ili CNS amiloidoze.
A method according to Claim 1, wherein the salt of hydrogen sulphide is sodium hydrogen sulfide, sodium sulfide, potassium hydrogen sulfide, calcium hydrogen sulfide or magnesium sulfide. 
Metoda prema patentnom zahtjevu 1, gdje je sol vodik sulfida natrij hidrogen sulfida, natrij sulfida, kalij hidrogen sulfida, kalcij hidrogen sulfida ili magnezij sulfida.
The compound of claim 1, wherein the modified oligonucleotide consists of 16 linked nucleosides and has a nucleobase sequence consisting of the sequence recited in SEQ ID NO: 549, wherein the modified oligonucleotide has: a gap segment consisting of ten linked deoxynucleosides; 
Spoj prema zahtjevu 5, gdje modificirani oligonukleotid se sastoji od 20 povezanih nukleozida koji imaju nukleobaznu sekvencu koja se sastoji od sekvence navedene u SEQ ID NO: 440, gdje modificirani oligonukleotid sadrži segment praznina koji se sastoji od deset povezanih deoksinukleozida;
a second peptide comprising a sequence consisting of a HLA-A*2402-restricted immunogenic epitope, wherein said first and second peptides are selected from the group consisting of the following pairs of peptides: 
(ii) drugi peptid koji sadrži slijed koji se sastoji od HLA-A*2402-restrikcijskog imunogeničnog epitopa, pri čemu su navedeni prvi i drugi peptidi odabrani 1z grupe koja se sastoji od sljedećih parova peptida:
• eye-related diseases, particularly wherein the eye-related disease is selected from the group consisting of retinopathy, macular degeneration, eye inflammation, corneal vascularization, vascular injection into the vitreous body, and vascularization of the eye lens, 
* > bolesti povezanih s očima, osobito gdje se bolest povezanu s očima bira iz skupine koju čine retinopatija, degeneracija makule, upala oka, vaskulariziranje rožnice, vaskularna injekcija u staklasto tijelo, te vaskulariziranje očne leće,
Selenite at a concentration ranging from about 0.003 to about 0.02 mg/L, preferably from about 0.005 to about 0.015 mg/L; Wheat hydrolysate at a concentration ranging from about 3000 to about 20000 mg/L, preferably from about 5000 to about 15000 mg/L; and 
HR P20070474 T3 hidrolizat pšenice u koncentraciji u rasponu od oko 3000 do oko 20000 mg/L, poželjno od oko 5000 do oko 15000 mg/L;i inzulin u koncentraciji u rasponu od oko 1 do oko 8 mg/L, poželjno od oko 2.5 do oko 6 mg/L.
Such systems comprising external columns may be designed, e.g., according to Example 1.1. and/or as described in Wang et al. 
Takav sustav, koji obuhvaća vanjsku kolonu, može biti dizajniran, primjerice sukladno Primjeru 1.1. i/ili kako je opisano u Wang i sur.
The method according to claim 19, wherein the condition is selected from cancers of the bladder, brain, breast and uterus, chronic lymphoid leukaemias, cancer of the colon, œsophagus and liver, lymphoblastic leukaemias, acute myeloid leukaemias, lymphomas, melanomas, malignant haemopathies, myelomas, ovarian cancer, non-small-cell lung cancer, prostate cancer, pancreatic cancer and small-cell lung cancer. 
Farmaceutski pripravak za uporabu u liječenju karcinoma u skladu s patentnim zahtjevom 20, naznačen time, da su karcinomi karcinom mokraćnog mjehura, mozga, dojke i maternice, kroničnih limfoidnih leukemija, karcinoma debelog crijeva, jednjaka i jetre, limfoblastičnih leukemija, akutnih mijeloidnih leukemija, limfoma, melanoma, zloćudne hemopatije, mijeloma, karcinoma jajnika, carcinoma pluća ne-malih stanica, karcinoma prostate, karcinoma gušterače i karcinoma pluća malih stanica.
measuring antibody-dependent cell-mediated cytotoxicity (ADCC) of natural killer (NK) cells against the target cell; and 
(b) mjerenja razine uništavanja ciljane stanice posredovanog NK stanicama u miša ili u uzorku mišjeg tkiva; i
Use of the dosage form according to any of claims 1 - 7 for the manufacture of a medicament for the prophylaxis or treatement of gastro-oesophageal reflux disease (GERD). 
Dozirni oblik za uporabu prema zahtjevu 11 ili 12, naznačen time, da kliničko stanje je gastro-ezofagealna refluksna bolest (GERD).
Thus, the polymerisation process may provide a hydrogel with an array of viscosities. 
Dakle, postupak polimerizacije može osigurati to, da se dobije hidrogel s nekim područjem viskoznosti.
A capsule according to claim 1, 2 or 3, wherein the at least one projection is provided on separate regions along a periphery of the capsule. 
Kapsula prema jednom od patentnih zahtjeva 1-3, pri čemu najmanje jedan ispupčeni dio (127) postoji na odvojenim područjima duž periferije kapsule (110).
The absorbent sheet according to embodiment 1, wherein at least a portion of the fiber of the domed region sidewalls exhibit fiber orientation bias in a direction toward the cap of the dome. 
Apsorbirajuća ploha (10) u skladu s patentnim zahtjevom 1, nadalje obuhvaća krestaste vlaknima obogaćene dijelove (24) s unakrsnim strojnim odmakom od orijentacije vlakana šupljinama nadsvođenih područja (12).
Intravenous administration of such a gel would most probably result in obstruction of blood vessels, associated with serious embolism or even death of the abuser. 
Intravenozna primjena odgovarajućeg gela dovela bi s velikom vjerojatnošću do začepljenja krvnih žila, povezanog s teškim zdravstvenim oštećenjima zlorabitelja.
Use of Claim 62, wherein the IL-17 antagonist is a humanized monoclonal antibody fragment or a fully human monoclonal antibody fragment. 
Uporaba u skladu sa zahtjevom 62, naznčena time, da IL-17 antagonist je fragment humaniziranog monoklonskog antitijela ili fragment potpuno ljudskog monoklonskog antitijela.
Crystalline form A and C of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide methanesulfonate, wherein crystalline form A has diffraction peaks at diffraction angles (2θ ± 0.2°) of 9.65° and 18.37° and wherein crystalline form C has diffraction peaks at diffraction angles (2θ ± 0.2°) of 14.20° and 17.59° in a powder X-ray diffraction measured according to "X-Ray Powder Diffration Method" described in Japanese Pharmacopoeia, 14th Edition, General Test utilizing the equipment and the condition as described in the description. 
Kristalni oblik A 1 C od 4-(3-kloro-4-(ciklopropilaminokarbonil)aminofenoksi)-7-metoksi-6-kinolinkarboksamid metansulfonata, naznačen time, da kristalni oblik A ima vrhove difrakcije kod kutova difrakcije (20 + 0,2%) od 9,65 * i 18,37 *, te time da kristalni oblik C ima vrhove difrakcije kod kutova difrakcije (20 + 0,2%) od 14,20% 1 17,59" kod rentgenske difrakcije na prahu, mjereno u skladu s "Postupkom rentgenske difrakcije praha" opisanom u 14. izdanju Japanske Farmakopeje, opći testovi uz uporabu opreme i s uvjetima kako je opisano u opisu.
Equal amounts of chloroform and water were added and the product extracted. 
Jednake količine kloroforma 1 vode su dodane i produkt je ekstrahiran.
In a study similar to the epitope mapping study on 2E7 using the Surface Plasmon Resonance assay described above, H2L1 behaved similarly to 2E7 in binding to the peptide encompassing amino acids 1-12 (AB1, SEQ ID No:15) of the B-amyloid peptide and not to the peptide encompassing amino acids 2-13 of the B-amyloid peptide (AB2-13, SEQ ID No:44). 
KD manju od 100 pM, te ima konstantu ravnoteže KD za vezanje na fB-amiloidni peptid 2-13 (SEQ ID No:44) koja je 1000 puta veća od one za peptid 1-12 (SEQ ID No:15), gdje su oba podatka dobivena ispitivanju površinskom plazmonskom rezonancijom uz upotrebu peptida vezanog na streptavidinski čip.
and converting the starting compound into a first taxane analog of the formula wherein: 
deoph i pretvaranje polaznog spoja u prvi analog taksana formule HE Qg op o
an antibody or a fragment thereof which specifically binds to said activated HGF B chain; or 
antitijelo ili njegov fragment koji se specifično veže na spomenuti aktivirani HGF B lanac; ili
Use of a compound according to any one of claims 1 to 32 or a pharmaceutically acceptable salt or solvate thereof in the manufacture of a medicament for the treatment of chronic obstructive pulmonary disease. 
Upotreba spoja, ili njegove farmaceutski prihvatljive soli ili solvata, u skladu s bilo kojim od patentnih zahtjeva 1 do 3, naznačena time što je navedeni spoj namijenjen proizvodnji medikamenta za liječenje kronične opstruktivno plućne bolesti.
New drugs are aimed at replacing methadone for opioid dependence, such as buprenorphine, however, only limited clinical study information is available (Fudula et al., NIDA Research Monograph 1991, 105:587-588). 
Novi lijekovi, kao što je buprenorfin, usmjereni su ka zamjenjivanju metadona kod opioidne ovisnosti, ali je, ipak, o kliničkom ispitivanju dostupna samo ograničena informacija (Fudula et al., NIDA Research Monograph 1991, 105:587-588).
reacting said compound of formula VI in an aprotic solvent with an alkali metal base to form a compound of formula VII wherein R1 and Rp1 and Rp2 have the meaning above, and 
oc) reakciji navedenog spoja formule VI, u neprotonskom otapalu, s bazom alkalnog metala kako bi se dobilo spoj formule VII gdje R1, te Rp; i Rp, imaju gore navedeno značenje, te
The fusion protein of claim 4 having the amino acid sequence set forth in SEQ ID NO: 105. 
Fuzijski protein prema najmanje jednom od patentnih zahtjeva 11 do 14, naznačen time da ima sekvencu kao što je navedeno u SEQ ID NO: 105.
an ultra-high pressure homogenizer 3 with a valve capable of working at high pressures for treating the preheated fluid at a pressure of between 200 and 600MPa, said homogenizer being configured to maintain the fluid at temperature Tu during 0,1 - 1s when coming out from the valve, Tu corresponding to the final temperature reached by the fluid at ultra-high homogeneizer valve; 
ultravisokotlačni homogenizator 3 s ventilom sposobnim za rad pri visokim tlakovima za tretiranje predgrijane tekućine kod tlaka između 200 i 600 MPa, navedeni homogenizator je konfiguriran za održavanje temperature Tu tijekom 0,1 – 1 s dok izlazi iz ventila, Tu odgovara konačnoj temperaturi dostignutoj tekućinom u ventilu ultravisokotlačnog homogenizatora;
Item 28 A method for stimulating intramolecular homologous recombination in the genome of a plant cell, the method comprising the step of: 
Postupak stimulacije intramolekularne homologne rekombinacije u genomu biljne stanice, naznačen time, da
Utility of compounds of the disclosure as screening agents 
Datum objave europskog patenta:
The mobile station apparatus according to claim 1, wherein two of DVRBs are mapped to two of the PRBs in the same frequency of a subframe, respectively. 
Integrirani krug sukladno jednom od zahtjeva 1 do 12, naznačen time da su dva od DVRB-a mapirana odgovarajuće na dva od PRB-ova na istoj frekvenciji podokvira.
is a bicyclic ring system which contains 9 to 11 ring members including 1 to 4 hetero atoms, independently selected from the group consisting N, O, and S, in which said bicyclic ring system may be substituted by 1 to 3 groups selected from the group consisting of C1-C6alkyl, substituted C1-C6alkyl, C3-C7cycloalkyl, halo, hydroxyl, oxo, amide, carboxylic acid, -C(O)Ra, -SO2Ra, arylalkyl, -(C1-C3alkyl)aryloxy, aryl, heteroaryl and C1-C4alkoxy, in which each Ra is independently C1-C6alkyl, substituted C1-C6alkyl or unsubstituted C3-C7cycloalkyl; each R2 and R3 is independently hydrogen, C1-C6alkyl, substituted C1-C6alkyl, halo, hydroxyl, amide, carboxylic acid or C1-C4alkoxy; and m is 0-2; 
R, je biciklički sustav prstena koji sadrži 9 do 11 članova u prstenu, uključujući 1 do 4 heteroatoma,, koje se neovisno bira iz skupine koju čine N, O, te S, gdje navedeni biciklički sustav prstena može biti supstituiran s 1 do 3 skupine, koje se bira iz skupine koju čine C,-Cy4alkil, supstituirani Cy-Cgalkil, C3-C;cikloalkil, halogen, hidroksil, okso, amid, karboksilna kiselina, -C(O)R,, -SO>R,, arilalkil, (C,-Csalkil)ariloksi, aril, heteroaril i C,-C,alkoksi, gdje je svaki R, neovisno C,-Csalkil, supstituirani C;-Csalkil ili nesupstituirani C3-Crcikloalkil; svaki R> i Rs je neovisno vodik, C,-Cgalkil, supstituirani C,-Csalkil, halogen, hidroksil, amid, karboksilna kiselina ili C,-Cualkoksi; i m je 0-2; ili njegova farmaceutski prihvatljiva sol.
a resin, particularly a resin selected from the group of: a Merrifield resin; a Rink-Amid resin; and a THP-resin; 
(i) smola, osobito smola odabrana iz skupine koju čine Merrifieldova smola; Rink-amid smola i THP-smola;
The method of claim 1, wherein the fusion protein comprises a first fibrinogen-like domain of angiopoietin-1 fused at its C-terminal end to the N-terminal end of an Fc fragment and the Fc fragment fused at its C-terminal end to the N-terminal end of a second fibrinogen-like domain of angiopoietin-1. 
Pripravak za primjenu u metodi prema bilo kojem patentnom zahtjevu od 1 do 9, naznačen time, što fuzijski protein sadrži prvu fibrinogensku domenu angiopoietina-1 spojenu na svom C-terminusu s N-terminusom Fc fragmenta i Fc fragment na svom C-terminusu spojen s N-terminusom druge fibrinogenske domene angiopoietina-1.
The process of claim 1 or claim 2, wherein at least a portion of asphaltenes in the resid are hydrocracked in the first reaction stage (14). 
Postupak u skladu s patentnim zahtjevom 1, naznačen time, da se barem dio asfaltena u ostatku hidrokrekira u prvom reakcijskom stupnju (14).
with an enzyme to yield the compound of Formula 3 and a compound of Formula 5, 
> s enzimom, kako bi se dobilo spoj Formule 3, ili njegovu sol, i spoj Formule 5 R!
The arrangement as claimed in claim 10 wherein the plenum chamber receives pressurised gas and the pressurised gas flows from the plenum chamber through the open passage and into the vessel. 
Sustav za sprječavanje izbacivanja plina iz prvog otvora spremnika prema bilo kojem od zahtjeva 7 ili 8, pri čemu plenum komora (44) prima plin pod pritiskom, a plin pod pritiskom teče iz plenumove komore (44) kroz otvoreni prolaz (48) i u spremnik(60).
The antibody for use according to claim 1 or claim 2, wherein the disease is Parkinson's disease. 
Antitijelo za upotrebu prema zahtjevu 1, pri čemu je bolest Parkinsonova bolest.
The method of 1, wherein the processing of the municipal solid waste stream includes shredding at least a portion of the waste stream to an average size of less than about 1 inch. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time, da obrada toka komunalnog krutog otpada uključuje usitnjavanje barem dijela toka otpada do prosječne veličine manje od 2,54 em (1 palac).
The compound of claim 9, chosen from: 
Spoj patentnog zahtjeva 9, izabrano od:
xi) expression of at least one marker for a neurotransmitter selected from the group consisting of dopamine, acetylcholine, and gamma aminobutyric acid (GABA); 
ekspresiju najmanje jednog neuronski-specifičnog antigena koji je izabran iz grupe koja obuhvaća neuronski-specifični tubulin, protein 2 koji se veže za mikrotubule, NCAM, i marker za neurotransmiter;
A composition comprising an effective amount of at least one antibody according to any of claims 1-5 for use in a method for diagnosing or treating an IL-23 related condition in a cell, tissue, organ or animal, wherein the IL-23 related condition is selected from the group consisting of psoriasis, psoriatic arthritis, Crohn's disease, multiple sclerosis, optic neuritis, and clinically isolated syndrome. 
Pripravak koji sadrži učinkovitu količinu najmanje jednog protutijela prema bilo kojem od zahtjeva 1-5 naznačen time što je za upotrebu u postupku određivanja dijagnoze ili liječenja stanja koje je povezano s IL-23 u stanici, tkivu, organu ili životinji, pri čemu je stanje koje je povezano s IL-23 odabrano iz skupine koja se sastoji od psorijaze, psorijaznog artritisa, Crohnove bolesti, multiple skleroze, optičkog neuritisa, i klinički izoliranog smdroma.
The method of claim 5, wherein the human is resistant to at least one chemotherapeutic agent. The method of claim 5, wherein the chronic lymphocytic leukemia or acute lymphocytic leukemia is refractory CD19+ leukemia. A method of generating a persisting population of genetically engineered T cells in a human diagnosed with cancer, the method comprising administering to the human a T cell genetically engineered to express a CAR wherein the CAR comprises a CD19 antigen binding domain, a transmembrane domain, a costimulatory signaling region comprising 4-1BB, and a CD3 zeta signaling domain comprising the amino acid sequence of SEQ ID NO: 24, wherein the persisting population of genetically engineered T cells persists in the human for at least one month after administration, and wherein the T cell is from a human having cancer. 
limfocitna leukemija. T stanica koja je genetski modificirana tako da eksprimira CAR, naznačena time što CAR sadrži (a) antigen- vezujuću domenu koja predstavlja anti-CD19 scFv koji sadrži aminokiselinsku sekvencu SEQ ID NO:20, (b) kostimulatornu signalnu regiju 4-1BB, i (c) signalnu domenu CD3 zeta koja sadrži aminokiselinsku sekvencu SEQ ID NO: 24, za upotrebu u postupku za liječenje karcinoma koji obuhvaća primjenu navedene T stanice kod čovjeka kome je dijagnosticiran karcinom, pri čemu navedeni postupak stvara populaciju genetski modificiranih T stanica koje perzistiraju u čovjeku najmanje osam mjeseci, devet mjeseci, deset mjeseci, jedanaest mjeseci, dvanaest mjeseci, dvije godine, ili tri godine nakon primjene, i pri čemu je čovjek otporan na liječenje najmanje jednim kemoterapeutskim sredstvom.